IPSC · Insider Trading
Century Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by IPSC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Brent Pfeiffenberger | President and CEO | F | −13,850 | −$26.87K |
| 2026-09-15 | Douglas Carr | SVP Finance & Operations | Sell | −1,658 | −$3.20K |
| 2026-09-15 | Gregory Russotti | See Remarks | Sell | −2,587 | −$4.99K |
| 2026-09-10 | Joseph Truitt | Director | A | +148,000 deriv. | — |
| 2026-09-09 | Douglas Carr | SVP Finance & Operations | Sell | −254 | −$521 |
| 2026-09-09 | Brent Pfeiffenberger | President and CEO | F | −463 | −$977 |
| 2026-09-09 | Gregory Russotti | See Remarks | Sell | −534 | −$1.09K |
| 2026-08-18 | Brent Pfeiffenberger | President and CEO | F | −31,172 | −$59.85K |
| 2026-08-05 | Douglas Carr | SVP Finance & Operations | Sell | −275 | −$544 |
| 2026-06-15 | Douglas Carr | SVP Finance & Operations | Sell | −1,654 | −$3.69K |
| 2026-06-15 | Brent Pfeiffenberger | President and CEO | F | −13,849 | −$31.02K |
| 2026-06-15 | Gregory Russotti | See Remarks | Sell | −2,584 | −$5.77K |
| 2026-06-15 | Chad Cowan | Chief Scientific Officer | F | −358 | −$802 |
| 2026-06-12 | Daphne Quimi | Director | A | +74,000 deriv. | — |
| 2026-06-12 | Alessandro Riva | Director | A | +74,000 deriv. | — |
| 2026-06-12 | Kimberly Blackwell | Director | A | +74,000 deriv. | — |
| 2026-06-12 | Martin Patrick Murphy | Director | A | +74,000 deriv. | — |
| 2026-06-12 | Han Myung Lee | Director | A | +74,000 deriv. | — |
| 2026-06-09 | Douglas Carr | SVP Finance & Operations | Sell | −249 | −$526 |
| 2026-06-09 | Brent Pfeiffenberger | President and CEO | F | −463 | −$986 |
| 2026-06-09 | Gregory Russotti | See Remarks | Sell | −524 | −$1.11K |
| 2026-05-19 | Brent Pfeiffenberger | President and CEO | F | −31,172 | −$72.94K |
| 2026-05-06 | Douglas Carr | SVP Finance & Operations | Sell | −264 | −$618 |
| 2026-04-10 | Martin Patrick Murphy | Director | A | +88,000 deriv. | — |
| 2026-04-03 | Chad Cowan | Chief Scientific Officer | F | −1,365 | −$2.99K |
| 2026-03-16 | Douglas Carr | SVP Finance & Operations | Sell | −7,043 | −$17.95K |
| 2026-03-16 | Gregory Russotti | See Remarks | Sell | −10,076 | −$25.68K |
| 2026-03-13 | Chad Cowan | Chief Scientific Officer | F | −1,431 | −$3.91K |
| 2026-03-13 | Brent Pfeiffenberger | President and CEO | F | −55,397 | −$151.23K |
| 2026-03-11 | Douglas Carr | SVP Finance & Operations | Sell | −247 | −$626 |
| 2026-03-11 | Gregory Russotti | See Remarks | Sell | −479 | −$1.21K |
| 2026-03-10 | Brent Pfeiffenberger | President and CEO | F | −463 | −$1.19K |
| 2026-02-18 | Brent Pfeiffenberger | President and CEO | F | −31,172 | −$54.55K |
| 2026-02-05 | Douglas Carr | SVP Finance & Operations | Sell | −323 | −$589 |
| 2026-02-04 | Douglas Carr | SVP Finance & Operations | A | +110,000 | — |
| 2026-02-04 | Gregory Russotti | See Remarks | A | +135,000 | — |
| 2026-02-04 | Chad Cowan | Chief Scientific Officer | A | +135,000 | — |
| 2026-02-04 | Brent Pfeiffenberger | President and CEO | A | +475,000 | — |
| 2026-01-06 | Chad Cowan | Chief Scientific Officer | F | −1,611 | −$1.60K |
| 2025-12-29 | Chad Cowan | Chief Scientific Officer | Buy | +58,060 | +$49.25K |
| 2025-12-16 | Brent Pfeiffenberger | President and CEO | Buy | +52,000 | +$30.35K |
| 2025-12-12 | Brent Pfeiffenberger | President and CEO | F | −463 | −$244 |
| 2025-12-11 | Han Myung Lee | Director | A | +88,000 deriv. | — |
| 2025-12-10 | Gregory Russotti | See Remarks | Sell | −526 | −$280 |
| 2025-12-10 | Douglas Carr | SVP Finance & Operations | Sell | −257 | −$137 |
| 2025-11-24 | Chad Cowan | Chief Scientific Officer | Sell | −5,462 | −$2.74K |
| 2025-11-20 | Brent Pfeiffenberger | President and CEO | Buy | +35,000 | +$17.33K |
| 2025-11-19 | Brent Pfeiffenberger | President and CEO | Sell | −32,456 | −$14.74K |
| 2025-11-05 | Douglas Carr | SVP Finance & Operations | Sell | −292 | −$171 |
| 2025-09-22 | Chad Cowan | Chief Scientific Officer | A | +762,543 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Brent Pfeiffenberger | President and CEO | 3,633,839 | $5.16M |
| Chad Cowan | Chief Scientific Officer | 1,186,019 | $1.68M |
| Gregory Russotti | See Remarks | 601,971 | $854.80K |
| Douglas Carr | SVP Finance & Operations | 502,907 | $714.13K |
| Adrienne Farid | Chief Operations Officer | 250,141 | $355.20K |
| Morgan Conn | Chief Finanical Officer | 79,648 | $113.10K |
| Daphne Quimi | Director | 5,000 | $7.10K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IPSC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.